MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers

BET inhibitors exhibit broad activity in cancer models, making predictive biomarkers challenging to define. Here we investigate the biomarkers of activity of the clinical BET inhibitor GSK525762 (I-BET; I-BET762) across cancer cell lines and demonstrate that KRAS mutations are novel resistance bioma...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncogenesis
Päätekijät: Wyce, Anastasia, Matteo, Jeanne J., Foley, Shawn W., Felitsky, Daniel J., Rajapurkar, Satyajit R., Zhang, Xi-Ping, Musso, Melissa C., Korenchuk, Susan, Karpinich, Natalie O., Keenan, Kathryn M., Stern, Melissa, Mathew, Lijoy K., McHugh, Charles F., McCabe, Michael T., Tummino, Peter J., Kruger, Ryan G., Carpenter, Christopher, Barbash, Olena
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5908790/
https://ncbi.nlm.nih.gov/pubmed/29674704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-018-0043-9
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia